145 results on '"J. Santos Juanes"'
Search Results
2. Psoriasis inducida por infliximab. Réplica.
- Author
-
Romero, M. Costa, Segura, P. Coto, and Jiménez, J. Santos-Juanes
- Published
- 2009
- Full Text
- View/download PDF
3. Sentinel lymph node biopsy versus observation in high-risk cutaneous squamous cell carcinoma in immunosuppressed and immunocompetent patients: An inverse probability of treatment weighting study.
- Author
-
Tejera-Vaquerizo A, Gómez-Tomás Á, Jaka A, Toll A, Del Río M, Ferrándiz-Pulido C, Fuente MJ, Carrasco C, Almazán-Fernández FM, Toledo-Pastrana T, Ferrer-Fuertes A, Ribero S, Avallone G, Cañueto J, Santos-Juanes J, and Sanmartín O
- Subjects
- Humans, Male, Retrospective Studies, Female, Aged, Middle Aged, Immunocompetence, Aged, 80 and over, Watchful Waiting, Disease-Free Survival, Skin Neoplasms pathology, Skin Neoplasms mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell mortality, Immunocompromised Host, Sentinel Lymph Node Biopsy
- Abstract
Background: The survival benefit of sentinel lymph node biopsy (SLNB) in immunocompetent and immunosuppressed patients with high-risk cutaneous squamous cell carcinoma (cSCC) has not been established., Objective: To determine whether SLNB improves disease-specific survival (DSS) in high-risk cSCC. Secondary objectives were to analyse disease-free survival, nodal recurrence-free survival and overall survival (OS)., Methods: Multicentre, retrospective, observational cohort study comparing survival outcomes in immunosuppressed and immunocompetent patients treated with SLNB or watchful waiting. Inverse probability of treatment weighting was used to adjust for possible confounding effects., Results: We studied 638 tumours in immunocompetent patients (SLNB n = 42, observation n = 596) and 173 tumours in immunosuppressed patients (SLNB n = 28, observation n = 145). Overall, SLNB was positive in 15.7% of tumours. SLNB was associated with a reduced risk of nodal recurrence (NR) (hazard ratio [HR], 0.05 [95% CI, 0.01-0.43]; p = 0.006), disease specific mortality (HR, 0.17 [95% CI, 0.04-0.72]; p = 0.016) and all-cause mortality (HR, 0.33 [95% CI, 0.15-0.71]; p = 0.004) only in immunocompetent patients., Conclusions: SLNB was associated with improvements in NR, DSS and OS in immunocompetent but not in immunosuppressed patients with high-risk cSCC., (© 2024 European Academy of Dermatology and Venereology.)
- Published
- 2024
- Full Text
- View/download PDF
4. Genetic polymorphisms to identify patients with an optimal response to tildrakizumab in psoriasis patients from real-life clinical practice.
- Author
-
Butrón-Bris B, Llamas-Velasco M, Ovejero-Benito MC, Santos-Juanes J, Martínez-López A, Ruiz-Villaverde R, Roustan G, Baniandrés O, Izu-Belloso R, de la Cueva P, Sahuquillo-Torralba A, Gónzalez-Quesada A, Vilarrasa-Rull E, Pujol-Montcusí J, García-Martínez J, Navares M, Palomar-Moreno I, Novalbos J, Abad-Santos F, Daudén E, and de la Fuente H
- Subjects
- Humans, Female, Male, Middle Aged, Adult, Polymorphism, Single Nucleotide, Treatment Outcome, Genotype, Aged, Polymorphism, Genetic, Psoriasis drug therapy, Psoriasis genetics, Antibodies, Monoclonal, Humanized therapeutic use
- Abstract
Detecting the association of genetic variants to the response of biological therapy represents an important advance in developing a personalized therapy. The aim of this work was to study the association of polymorphisms with an optimal response to tildrakizumab in patients with psoriasis in a real-life clinical practice. Ninety patients with plaque psoriasis recruited from-Spanish hospitals receiving tildrakizumab for at least 24 weeks were genotyped for 180 polymorphisms. Optimal response to tildrakizumab was evaluated by absolute PASI ≤1 at 6 and 12 months. Polymorphisms corrected for weight and disease duration with an FDR <0.15 were included in a multiple regression model. Sixty three percent of patients achieved an absolute PASI ≤1 at 6 months, while 71% did so after 12 months. Disease duration (>27 years) and weight (>76 kg) were associated with treatment response; after correcting by these factors, no association (FDR >0.15) was found for any polymorphism and response to tildrakizumab at 6 months. The analysis at 12 months identified the genotype GG for rs610604 (TNFAIP3), CT for rs9373839 (ATG5), and delCTGT/delCTGT for rs72167053 (PDE4D) as risk factors to not achieve an optimal response (PASI ≤1), while CT for rs708567 (IL17RC) was protective, independently of weight and disease duration (FDR <0.15). The final multivariable model at 12 months showed an AUC of 0.90 (95% CI 0.82 to -0.98). We identified a set of polymorphisms that could be helpful to identify psoriatic patients with an optimal response to tildrakizumab at 12 months in real-world practice conditions., (© 2024 The Author(s). Experimental Dermatology published by John Wiley & Sons Ltd.)
- Published
- 2024
- Full Text
- View/download PDF
5. Do patients with inflammatory bowel disease really know what other immune-mediated inflammatory diseases they are diagnosed with?
- Author
-
de Francisco R, Pérez-Martínez I, Castaño-García A, Carballo-Folgoso L, Flórez-Díez P, García-Pérez C, Fernández-González E, Rolle V, Chiminazzo V, Queiro R, Alonso-Castro S, Santos-Juanes J, Gueimonde M, and Riestra S
- Abstract
Background and Aims: The association of inflammatory bowel disease (IBD) with other immune-mediated inflammatory diseases (IMIDs) in the same patient is well known. We aimed to evaluate the degree of knowledge that patients with IBD have regarding the coexistence of other IMIDs and to analyze the factors associated with the concordance between self-reported and confirmed medical information., Methods: Patients with IBD at a tertiary hospital answered a questionnaire on the presence of 54 IMIDs (self-reported diagnosis), and their IMID diagnosis was confirmed in their medical records (reference diagnosis). Agreement between the self-reported IMID and the IMID according to medical records was evaluated. The association between concordance and different predictors was evaluated using logistic regression models., Results: A total of 1,620 patients were included. Six hundred and twenty-six (39%) patients were diagnosed with at least one IMID, and 177 (11%) with two or more. Overall agreement between patients´ self-report and medical records was k:0.61. When we grouped IMIDs according to affected organs or systems, agreement on rheumatic IMIDs was moderate (k:0.58), whereas agreement on cutaneous (k:0.66), endocrine (k: 0.74) and ocular (k:0.73) IMIDs was substantial. Among patients who had IMIDs, the factor associated with greater concordance was female gender, while lower concordance was associated with a lower educational level and the fact that the IMID had been diagnosed at the same time or later than IBD., Conclusion: The knowledge that patients with IBD have regarding the coexistence of other IMIDs is poor, especially in rheumatic IMIDs., (© The Author(s) 2024. Published by Oxford University Press on behalf of European Crohn’s and Colitis Organisation. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
6. [Translated article] Validation of the Spanish Version of the PURE-4 Questionnaire for the Early Detection of Psoriatic Arthritis in Psoriatic Patients.
- Author
-
Belinchón-Romero I, López-Ferrer A, Ferrán I Farrés M, Rivera-Díaz R, Vidal-Sarro D, Rodríguez Fernández-Freire L, de la Cueva-Dobao P, Santos-Juanes J, Rocamora-Durán V, Martín-Vázquez V, Gómez-Labradror L, and Queiro-Silva R
- Subjects
- Humans, Female, Cross-Sectional Studies, Male, Middle Aged, Adult, Surveys and Questionnaires, Reproducibility of Results, Translations, Sensitivity and Specificity, Spain, Feasibility Studies, Language, Arthritis, Psoriatic diagnosis, Early Diagnosis, Psoriasis diagnosis
- Abstract
Background and Objective: Psoriasis often precedes the onset of psoriatic arthritis (PsA), so dermatologists often face the challenge of early identifying signs of PsA in patients with psoriasis. Our aim was to validate the Spanish version of the PURE-4 questionnaire as a screening tool for PsA, evaluate its performance in terms of sensitivity, specificity, feasibility, reliability, and build validity., Methods: This was a cross-sectional, observational, multicenter trial of adult patients with psoriasis. Initially, patients were assessed by a dermatologist and completed 2 self-administered versions (in print and online) of the PURE-4 questionnaire. Afterwards, the rheumatologist, blinded to the PURE-4 results, assessed the presence/absence of PsA, being the reference to determine the performance of the PURE-4 questionnaire., Results: A total of 268 patients were included (115 [42.9%] women; mean age, 47.1±12.6). The prevalence of PsA according to rheumatologist diagnosis was 12.7% (34 patients). The mean PURE-4 score for patients with psoriasis diagnosed with PsA was 2.3±1.1, and 1.3±1.3 for patients without PsA (P<.001). The cutoff value ≥2 demonstrated the best performance for detecting PsA, with a negative predictive value of 95.1% (95% confidence interval, 90.3-97.6)., Conclusions: The PURE-4 questionnaire demonstrated good performance in detecting PsA, with an optimal cutoff point ≥2. This simple tool could facilitate early referral of patients to the rheumatology unit., (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
7. [Translated article] Longitudinal Study of Different Progression Patterns in High-Risk Cutaneous Squamous Cell Carcinoma.
- Author
-
Tejera-Vaquerizo A, Cañueto J, Gómez-Tomás A, Santos-Juanes J, Ribero S, Avallone G, Jaka A, Ferrandiz-Pulido C, Toll A, and Sanmartín O
- Subjects
- Humans, Retrospective Studies, Male, Female, Longitudinal Studies, Aged, Middle Aged, Aged, 80 and over, Neoplasm Recurrence, Local epidemiology, Skin Neoplasms pathology, Skin Neoplasms mortality, Carcinoma, Squamous Cell pathology, Carcinoma, Squamous Cell mortality, Carcinoma, Squamous Cell secondary, Disease Progression, Lymphatic Metastasis pathology
- Abstract
Background and Objective: Cutaneous squamous cell carcinoma (cSCC) is the second leading cause of skin cancer mortality in Europe. Few studies have analyzed the different pathways of this tumor progression in its natural history. The main objective of this study was to analyze the different metastatic and progression pathways and their temporal occurrence in the evolution of cSCC., Material and Method: We conducted a multicenter, retrospective, and observational study of consecutive high-risk sSCCs included in the SQUAMATA project., Results: A total of 222 out of the 1346 patients included relapsed. The most frequent route of progression was the lymphatic one (62.6%). A total of 20.2% of the cases with lymphatic progression developed distant metastases. Only 1 case (3.1%) of distant metastasis followed local recurrence without previous lymphatic metastasis. The median time to disease-related mortality was longer in patients who developed systemic metastases than in those who died of locoregional progression., Conclusions: The mortality of patients with cSCC is mostly due to the regional progression of their lymphatic metastases. The appearance of distant metastases is practically always (96.9%) associated with previous lymphatic metastatic progression. Therefore, in the future, new studies will be needed to assess the regional management of cSCC in both surgical and adjuvant therapies., (Copyright © 2024 AEDV. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2024
- Full Text
- View/download PDF
8. Low-Level Expression of p-S6 Is Associated with Nodal Metastasis in Patients with Head and Neck Cutaneous Squamous Cell Carcinoma.
- Author
-
Gómez-de Castro C, Santos-Juanes R, Nuñez-Gómez B, Fernández-Vega I, Vivanco B, Fernández-Velasco A, Reyes-García S, Carrero-Martín J, García-Pedrero JM, Rodrigo JP, González-Vela MDC, Santos-Juanes J, and Galache C
- Subjects
- Humans, Male, Female, Middle Aged, Aged, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Prognosis, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell pathology, Aged, 80 and over, Biomarkers, Tumor metabolism, Squamous Cell Carcinoma of Head and Neck metabolism, Squamous Cell Carcinoma of Head and Neck pathology, Adult, Kaplan-Meier Estimate, Proportional Hazards Models, Immunohistochemistry, Lymphatic Metastasis, Skin Neoplasms pathology, Skin Neoplasms metabolism, Head and Neck Neoplasms pathology, Head and Neck Neoplasms metabolism
- Abstract
Cutaneous squamous cell carcinoma (cSCC) is the second most common form of skin cancer. The incidence of metastasis for cSCC is estimated to be around 1.2-5%. Ribosomal protein S6 (p-S6) and the p21 protein (p21) are two proteins that play central roles in other cancers. These proteins may be equally important in cSCC, and together, these could constitute a good candidate for metastasis risk assessment of these patients. We investigate the relationship of p-S6 and p21 expression with the impact on the prognosis of head and neck cSCC (cSCCHN). p-S6 and p21 expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 116 patients with cSCCHN and associations sought with clinical characteristics. Kaplan-Meier estimators and Cox proportional hazard regression models were also used. The expression of p-S6 was significantly inversely associated with tumor thickness, tumor size, desmoplastic growth, pathological stage, perineural invasion and tumor buds. p21 expression was significantly inversely correlated with >6 mm tumor thickness, desmoplastic growth, and perineural invasion. p-S6-negative expression significantly predicted an increased risk of nodal metastasis (HR = 2.63, 95% CI 1.51-4.54; p < 0.001). p21 expression was not found to be a significant risk factor for nodal metastasis. These findings demonstrate that p-S6-negative expression is an independent predictor of nodal metastasis. The immunohistochemical expression of p-S6 might aid in better risk stratification and management of patients with cSCCHN.
- Published
- 2024
- Full Text
- View/download PDF
9. Annular lichenoid dermatitis of youth.
- Author
-
Aubán-Pariente J, Santos-Juanes J, Vivanco-Allende B, and Galache-Osuna C
- Subjects
- Humans, Child, Male, Female, Adolescent, Dermatitis diagnosis, Dermatitis etiology, Dermatitis pathology, Lichenoid Eruptions diagnosis, Lichenoid Eruptions pathology
- Published
- 2024
- Full Text
- View/download PDF
10. Effectiveness and safety of tildrakizumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group.
- Author
-
Berenguer-Ruiz S, Aparicio-Domínguez M, Herranz-Pinto P, Ruíz-Villaverde R, López-Ferrer A, Santos-Juanes J, Rodríguez Fernández-Freire L, Hospital-Gil M, Arias-Santiago S, Carretero-Hernández G, Mateu-Puchades A, Ferran M, Del Alcázar E, Santos-Alarcón S, Garcia-Latasa de Aranibar FJ, Belinchón-Romero I, González-Cantero Á, Ruíz-Genao D, Eiris-Salvado N, Rocamora-Durán V, Rivera-Diaz R, de la Cueva P, Daudén E, Salgado-Boquete L, and Llamas-Velasco M
- Subjects
- Female, Humans, Male, Middle Aged, Retrospective Studies, Severity of Illness Index, Treatment Outcome, Arthritis, Psoriatic drug therapy, Psoriasis drug therapy
- Abstract
Background: Tildrakizumab is a humanized, IgG1/κ antibody that interacts with the p19 subunit of interleukin 23. It is approved for the treatment of moderate-to-severe plaque psoriasis. Real-world evidence on the effectiveness and safety of tildrakizumab is limited., Objectives: To assess the effectiveness and safety of tildrakizumab at 24 weeks in patients with moderate-to-severe plaque psoriasis in routine clinical practice., Methods: Retrospective, observational, multicentre study including adult patients with moderate-to-severe plaque psoriasis treated with tildrakizumab under real-life conditions. Patient data were extracted from anonymized electronic medical records. Statistical analysis was performed using SPSS22., Results: A total of 190 patients were included. About 53.9% were men with a mean age of 51.45 (SD 3.9) and a mean BMI of 29.13 (SD 6.21). About 79.8% (132 out of 190) of patients had previously received biological therapy (BT) and 17.3% (33 out of 191) had psoriatic arthritis. Baseline PASI was 10.7 (SD 6.53). Up to 109 patients reached Week 24 and at this point mean baseline PASI decreased to 1.7 (SD 4.8), representing an 88.79% mean PASI reduction. At 6 months, 87.1% and 40.3% of the treated patients achieved PASI ≤3 and ≤1, respectively. At Week 24 mean BSA decreased from 13.2 (SD 10.07) to 1.6 (SD 4.40) and mean DLQI went from 12.5 (SD 7.12) to 1.2 (SD 3.27). Multivariate analysis showed no differences when effectiveness was correlated with gender, obesity, psoriatic arthritis or prior exposure to BT. The rate of adverse events (AE) was 5.9% (11 out of 190), where infections were the most frequent AE (4 out of 11). One patient suffered a haemorrhagic ictus and one patient died due to causes unrelated to the study., Conclusion: Tildrakizumab was effective and safe in a large cohort of patients with moderate-to-severe plaque psoriasis treated in a routine clinical setting., (© 2023 European Academy of Dermatology and Venereology.)
- Published
- 2023
- Full Text
- View/download PDF
11. PINK1 Immunoexpression Predicts Survival in Patients Undergoing Hepatic Resection for Colorectal Liver Metastases.
- Author
-
Celis-Pinto JC, Fernández-Velasco AA, Corte-Torres MD, Santos-Juanes J, Blanco-Agudín N, Piña Batista KM, Merayo-Lloves J, Quirós LM, and Fernández-Vega I
- Subjects
- Humans, Hepatectomy, Retrospective Studies, Protein Kinases genetics, Liver Neoplasms secondary, Colorectal Neoplasms genetics, Colorectal Neoplasms surgery
- Abstract
PTEN-induced kinase-1 (PINK1) is the initiator of the canonical mitophagy pathway. Our aim was to study the immunoexpression of PINK1 in surgical specimens from ninety patients with metastatic colorectal adenocarcinoma (CRC) to the liver (CRLM). Tissue arrays were produced, and immunohistochemical studies were analyzed by the H-Score method. The mean immunoexpression of PINK1 in normal tissues was between 40 to 100 points. In tumoral tissues, positive PINK1 immunoexpression was observed in all samples, and no differences were noted between CRCs. In CRLMs, a significant under-expression was noted for PINK1 from the rectum (71.3 ± 30.8; p < 0.042) compared to other sites. Altered PINK1 immunoexpression in CRCs, either higher than 100 points or lower than 40 points, was associated with worse overall survival (OS) ( p < 0.012) due to a shorter post-metastatic survival (PMS) ( p < 0.023), and it was found to be a significant independent predictor of prognosis in a multivariate model for OS and PMS (HR = 1.972, 95% CI 0.971-4.005; p = 0.022. HR = 2.023, 95% CI 1.003-4.091; p = 0.037, respectively). In conclusion, altered PINK1 immunoexpression determined in CRCs with resected CRLM predicts a worse prognosis, possibly due to the abnormal function of mitophagy.
- Published
- 2023
- Full Text
- View/download PDF
12. The TINCR ubiquitin-like microprotein is a tumor suppressor in squamous cell carcinoma.
- Author
-
Morgado-Palacin L, Brown JA, Martinez TF, Garcia-Pedrero JM, Forouhar F, Quinn SA, Reglero C, Vaughan J, Heydary YH, Donaldson C, Rodriguez-Perales S, Allonca E, Granda-Diaz R, Fernandez AF, Fraga MF, Kim AL, Santos-Juanes J, Owens DM, Rodrigo JP, Saghatelian A, and Ferrando AA
- Subjects
- Animals, Mice, Humans, Ubiquitin metabolism, Genes, Tumor Suppressor, Keratinocytes metabolism, Cell Line, Tumor, Gene Expression Regulation, Neoplastic, Micropeptides, Carcinoma, Squamous Cell genetics, Head and Neck Neoplasms genetics, RNA, Long Noncoding genetics
- Abstract
The TINCR (Terminal differentiation-Induced Non-Coding RNA) gene is selectively expressed in epithelium tissues and is involved in the control of human epidermal differentiation and wound healing. Despite its initial report as a long non-coding RNA, the TINCR locus codes for a highly conserved ubiquitin-like microprotein associated with keratinocyte differentiation. Here we report the identification of TINCR as a tumor suppressor in squamous cell carcinoma (SCC). TINCR is upregulated by UV-induced DNA damage in a TP53-dependent manner in human keratinocytes. Decreased TINCR protein expression is prevalently found in skin and head and neck squamous cell tumors and TINCR expression suppresses the growth of SCC cells in vitro and in vivo. Consistently, Tincr knockout mice show accelerated tumor development following UVB skin carcinogenesis and increased penetrance of invasive SCCs. Finally, genetic analyses identify loss-of-function mutations and deletions encompassing the TINCR gene in SCC clinical samples supporting a tumor suppressor role in human cancer. Altogether, these results demonstrate a role for TINCR as protein coding tumor suppressor gene recurrently lost in squamous cell carcinomas., (© 2023. The Author(s).)
- Published
- 2023
- Full Text
- View/download PDF
13. Psoriasis of the external auditory canal: prevalence, clinical features and impact on quality of life.
- Author
-
Galache C, Vázquez-Losada B, Armesto S, González-Gay MA, Vázquez-López F, and Santos-Juanes J
- Subjects
- Humans, Prevalence, Prospective Studies, Ear Canal, Severity of Illness Index, Pruritus etiology, Pruritus complications, Quality of Life, Psoriasis complications
- Abstract
Psoriasis of the external auditory canal (PsEAC) is often under-recognized. The aims of this study were to assess the prevalence of PsEAC, its association with a particular psoriasis subtype and its impact on quality of life (QoL). A prospective study was carried out in two Spanish university hospitals, enrolling consecutive patients who attended a consultation for psoriasis. The clinical features of psoriasis and PsEAC were recorded and the Dermatology Life Quality Index (DLQI) and Itch Numerical Rating Scale (Itch-NRS) were distributed to patients. Overall, 188 of 1000 patients (18.8%) included in the study had PsEAC, which was associated with severity of psoriasis, presence of inverse psoriasis and involvement of the scalp, nails and genitals, but not with obesity or psoriatic arthritis. PsEAC was the main reason for consultation in 27 patients, with itching being the main symptom. In this study, PsEAC had a prevalence of 18.8%. The occurrence of PsEAC was associated with poorer QoL, as measured by DLQI and Itch-NRS., (© 2022 British Association of Dermatologists.)
- Published
- 2022
- Full Text
- View/download PDF
14. Drug survival of adalimumab biosimilars in real-world treatment of psoriasis: A Spanish multicenter study.
- Author
-
López-Ferrer A, Vilarrasa E, Armesto S, Santos-Juanes J, Galache C, Carretero G, Sahuquillo A, Salgado-Boquete L, Del Alcázar E, González-Cantero A, Martorell A, Rivera-Díaz R, Mitxelena-Ezeiza J, Mateu A, Belinchón I, Llamas-Velasco M, Riera-Monroig J, Lázaro A, López-Estebaranz JL, Gich I, and Puig L
- Subjects
- Humans, Adalimumab therapeutic use, Infliximab therapeutic use, Etanercept therapeutic use, Biosimilar Pharmaceuticals therapeutic use, Psoriasis drug therapy
- Published
- 2022
- Full Text
- View/download PDF
15. Retrospective study of apremilast drug survival in psoriasis patients in a daily practice setting: A long-term experience.
- Author
-
Galache-Osuna C, Reyes-García S, Salgueiro E, Bordallo-Landa J, Lozano A, Vázquez-López F, and Santos-Juanes J
- Subjects
- Humans, Retrospective Studies, Severity of Illness Index, Thalidomide analogs & derivatives, Treatment Outcome, Anti-Inflammatory Agents, Non-Steroidal therapeutic use, Psoriasis chemically induced, Psoriasis diagnosis, Psoriasis drug therapy
- Abstract
There is limited evidence about the real-world survival of apremilast in patients with psoriasis, especially over the long term. To evaluate the long-term survival of apremilast and its predictive factors when used to treat psoriasis. A retrospective hospital-based study, including data collected from 104 patients. Survival curves were estimated using the Kaplan-Meier estimator. Proportional hazard Cox regression models were used for multivariate analysis. The average duration of the treatment before discontinuation was 28.82 months (95% CI, 22.08-35.57 months) and the median was 12 months (95% CI, 2.68-21.31 months). The retention rates were 51% (1 year), and 33% (5 years). The survival study revealed statistically significant differences between patients with PASI<10 and those in the PASI≥10 group (log-rank test, p < 0.001). The 5-year prevalences were 64% for patients with a PASI of <10 and 5% for those with an index ≥10. In the PASI < 10-patient group, the retention rates were 77% (1 year) and 64% (5 years). Furthermore, 66% of patients who continued apremilast treatment for more than 2 years were receiving off-label doses (30 mg/day). Apremilast may be a suitable and efficient alternative for the treatment of psoriasis patients in the PASI<10 group., (© 2022 Wiley Periodicals LLC.)
- Published
- 2022
- Full Text
- View/download PDF
16. Therapeutic success of sodium thiosulfate in treating cutaneous calciphylaxis in a patient with hyperphosphataemic familial tumoral calcinosis.
- Author
-
Requena S, Santos-Juanes J, Morales P, and Gómez C
- Subjects
- Aged, Humans, Male, Antioxidants therapeutic use, Calcinosis drug therapy, Calciphylaxis drug therapy, Hyperostosis, Cortical, Congenital drug therapy, Hyperphosphatemia drug therapy, Thiosulfates therapeutic use
- Abstract
Calciphylaxis is a potencially disorder in patients with hyperphosphatemic familial tumoral calcinosis (HFTC). Patients commonly present livedo racemosa and retiform purpura, which may progress to necrosis and very painful ulcers. Treatment with sodium thiosulfate provides good results; however, intralesional and intravenous treatment can be limited by its adverse effects. Topical sodium thiosulfate has been successfully reported for cutaneous calcification associated with connective tissue diseases and calciphylaxis in patients with chronic kidney disease. We provide a case report of a patient with HFTC and calciphylaxis who was treated with topical sodium thiosulfate with a rapid and complete response with no side effects., (© 2021 The Australasian College of Dermatologists.)
- Published
- 2022
- Full Text
- View/download PDF
17. Use of Biological Treatments in Elderly Patients with Skin Psoriasis in the Real World.
- Author
-
Osuna CG, García SR, Martín JC, Jiménez VG, López FV, and Santos-Juanes J
- Abstract
Biological drugs have prompted a revolution in the treatment of patients with psoriasis because of their favourable efficacy/risk profile. The aims of our study are to determine whether there is any difference in the pattern of use of biological treatments for older (65+ years) and younger patients diagnosed with plaque psoriasis by the Dermatology Service of the Hospital Universitario de Asturias (HUCA), to understand the survival of these drugs, and to identify the factors that predict the discontinuation of treatments. We report a retrospective observational hospital-based study of 300 patients registered at HUCA's Dermatology Service who were receiving one of the following biological treatments for psoriasis on 30 November 2020: adalimumab, ustekinumab, secukinumab, or ixekizumab. The age groups were compared using Student's t-test for quantitative variables and the chi-squared test for qualitative variables. We used the Kaplan-Meier estimator to estimate the survival function and the log-rank test to measure differences. No statistically significant differences in the frequency of use were noted between the younger and older groups, for any of the drugs studied. Survival on a drug regime, globally and individually, was similar in the two age groups. Factors predicting lower overall survival were being female, obesity, and having undergone previous biological treatment. The first three factors were influential in the under-65-year-old group, while arthritis was a significant factor for the older group.
- Published
- 2021
- Full Text
- View/download PDF
18. Effects of COVID-19 Lockdown on Tumour Burden of Melanoma and Cutaneous Squamous Cell Carcinoma.
- Author
-
Tejera-Vaquerizo A, Paradela S, Toll A, Santos-Juanes J, Jaka A, López A, Cañueto J, Bernal À, Villegas-Romero I, Ferrándiz-Pulido C, Perandones H, Moreno-Ramírez D, Domínguez-Mahamud C, Salido-Vallejo R, Sanmartin O, Almazán-Fernández FM, Rodríguez-Jiménez P, Bañuls J, Podlipnik S, Sandoval-Clavijo A, Boada A, García-Bracamonte B, Palencia S, Revilla-Nevreda D, Reola-Ramírez E, Del Carmen Gómez-Mateo M, Linares-Barrios M, Jiménez-Gallo D, González-Cruz C, Samaniego E, Navedo-de Las Heras M, Taberner R, Ródenas-Herranz T, García-Donoso C, Puig S, and Nagore E
- Subjects
- Communicable Disease Control, Humans, Pandemics, SARS-CoV-2, Tumor Burden, COVID-19, Carcinoma, Squamous Cell epidemiology, Carcinoma, Squamous Cell surgery, Melanoma epidemiology, Melanoma surgery, Skin Neoplasms epidemiology, Skin Neoplasms surgery
- Abstract
The aim of this study was to compare tumour burden in patients who underwent surgery for melanoma and cutaneous squamous cell carcinoma during nationwide lockdown in Spain due to COVID-19 (for the period 14 March to 13 June 2020) and during the same dates in 2019 before the COVID-19 pandemic. In addition, associations between median tumour burden (Breslow thickness for melanoma and maximum clinical diameter for cutaneous squamous cell carcinoma) and demographic, clinical, and medical factors were analysed, building a multivariate linear regression model. During the 3 months of lockdown, there was a significant decrease in skin tumours operated on (41% decrease for melanoma (n = 352 vs n = 207) and 44% decrease for cutaneous squamous cell carcinoma (n = 770 vs n = 429)) compared with the previous year. The proportion of large skin tumours operated on increased. Fear of SARS-CoV-2 infection, with respect to family member/close contact, and detection of the lesion by the patient or doctor, were related to thicker melanomas; and fear of being diagnosed with cancer, and detection of the lesion by the patient or relatives, were related to larger size cutaneous squamous cell carcinoma. In conclusion, lockdown due to COVID-19 has resulted in a reduction in treatment of skin cancer.
- Published
- 2021
- Full Text
- View/download PDF
19. Paraneoplastic erythema annulare centrifugum eruption (PEACE).
- Author
-
Aubán Pariente J, Gómez Vila B, Vázquez Losada B, and Santos-Juanes J
- Subjects
- Autoantibodies, Erythema diagnosis, Erythema etiology, Humans, Exanthema, Skin Diseases, Genetic
- Published
- 2021
- Full Text
- View/download PDF
20. Acne Inversa-like Lesions Induced by a Low Dose of Sorafenib.
- Author
-
Aubán-Pariente J, Palacios-García L, Galache-Osuna C, Mir-Bonafé M, Del Burgo PM, and Santos-Juanes J
- Abstract
Competing Interests: Competing interests: The authors have no conflicts of interest to disclose.
- Published
- 2021
- Full Text
- View/download PDF
21. Immunohistochemical expression analysis of MMP-1, TIMP-2 and p53 in Barrett's esophagus, dysplasia and esophageal adenocarcinoma.
- Author
-
García-Varona A, Fernández-Vega I, and Santos-Juanes J
- Subjects
- Humans, Matrix Metalloproteinase 1, Retrospective Studies, Tissue Inhibitor of Metalloproteinase-2, Tumor Suppressor Protein p53, Adenocarcinoma, Barrett Esophagus
- Abstract
Barrett's esophagus (BE) is the most important risk factor for the development of esophageal adenocarcinoma. It develops through a progressive sequence of histologic and molecular events that begin with metaplasia and then progresses through various stages of dysplasia. Matrix metalloproteinases are involved in the degradation of the extracellular matrix and play an important role in tumor progression. The immunohistochemical expression of MMP-1, TIMP-2 and p53 in 111 samples from 45 patients diagnosed with BE with and without dysplasia and adenocarcinoma of the esophagus was retrospectively studied, and statistical analysis was conducted to measure the association between their expression and the degree of dysplasia present. MMP-1 was expressed in 33.3% of the samples studied, mainly in the adenocarcinoma subgroup with up to 40% positive cases (p = 0.494). In contrast, TIMP-2 was expressed in 25.2% of the samples, and no positive cases were identified in the adenocarcinoma subgroup (p = 0.037). Aberrant p53 expression was observed in 81.4% of the samples diagnosed with some degree of dysplasia (p < 0.001). MMP-1 showed no statistically significant differences between diagnostic entities. A statistically significant loss of TIMP-2 expression was observed in distal esophageal adenocarcinoma samples, which contrasts with the aberrant expression of p53 in dysplastic cases.
- Published
- 2021
- Full Text
- View/download PDF
22. Ustekinumab Drug Survival in Patients with Psoriasis: A retrospective Study of Real Clinical Practice.
- Author
-
Galache Osuna C, Gómez-Vila B, Aubán Pariente J, Vázquez Losada B, Gómez de Castro C, Requena López S, de Dios Velázquez Á, Palacios García L, Ordoñez Fernández L, Gómez Diez S, Vázquez López F, and Santos-Juanes J
- Subjects
- Adalimumab, Humans, Retrospective Studies, Treatment Outcome, Ustekinumab therapeutic use, Pharmaceutical Preparations, Psoriasis drug therapy
- Abstract
Background and objectives: The efficacy and safety of ustekinumab have been proved in clinical trials. In daily clinical practice, knowing the factors that determine survival differences of biological drugs allows psoriasis treatment to be optimized as a function of patient characteristics. The main objectives of this work are to understand ustekinumab drug survival in patients diagnosed with plaque psoriasis in the Hospital Universitario Central de Asturias (HUCA Dermatology Department, and to identify the predictors of drug discontinuation. Materials and Methods : A retrospective hospital-based study, including data from 148 patients who were receiving ustekinumab (Stelara
® ) between 1 February 2009 and 30 November 2019, were collected. Survival curves were approximated through the Kaplan-Meier estimator and compared using the log-rank test. Proportional hazard Cox regression models were used for multivariate analyses while both unadjusted and adjusted hazard ratios (HR) were used for summarizing the studied differences. Results: The average duration of the treatment before discontinuation was 47.57 months (SD 32.63 months; median 41 months). The retention rates were 82% (2 years), 66% (5 years), and 58% (8 years). Median survival was 80 months (95% confidence interval. CI 36.9 to 123.01 months). The survival study revealed statistically significant differences between patients with arthritis (log-rank test, p < 0.001) and those who had previously received biological treatment (log-rank test, p = 0.026). The five-year prevalence in patients still under treatment was 80% (those without arthritis) and 54% (arthritis patients). In the multivariate analysis, only the patients with arthritis had a lower rate of drug survival. No statistically significant differences were observed for any of the other comorbidities studied. The first and second most frequent causes of discontinuation were secondary failure and arthritis inefficacy, respectively. Conclusion: Ustekinumab is a biological drug conferring high survival in plaque psoriasis patients. Ustekinumab survival is lower in patients with arthritis.- Published
- 2020
- Full Text
- View/download PDF
23. [Estimated Effect of COVID-19 Lockdown on Skin Tumor Size and Survival: An Exponential Growth Model].
- Author
-
Tejera-Vaquerizo A, Cañueto J, Toll A, Santos-Juanes J, Jaka A, Ferrandiz-Pulido C, Sanmartín O, Ribero S, Moreno-Ramírez D, Almazán F, Fuente MJ, Podlipnik S, and Nagore E
- Subjects
- Age Factors, Algorithms, COVID-19, Carcinoma, Squamous Cell mortality, Delayed Diagnosis adverse effects, Delayed Diagnosis statistics & numerical data, Female, Head and Neck Neoplasms mortality, Health Services Accessibility, Humans, Male, Melanoma mortality, Pandemics, Public Health Surveillance methods, Quarantine, Retrospective Studies, SARS-CoV-2, Sex Factors, Skin Neoplasms mortality, Spain epidemiology, Time Factors, Time-to-Treatment, Betacoronavirus, Carcinoma, Squamous Cell pathology, Coronavirus Infections epidemiology, Head and Neck Neoplasms pathology, Melanoma pathology, Pneumonia, Viral epidemiology, Skin Neoplasms pathology, Tumor Burden
- Abstract
Background and Objectives: Spain is in a situation of indefinite lockdown due to the ongoing coronavirus disease 2019 (COVID-19) pandemic. One of the consequences of this lockdown is delays in medical and surgical procedures for common diseases. The aim of this study was to model the impact on survival of tumor growth caused by such delays in patients with squamous cell carcinoma (SCC) and melanoma., Material and Methods: Multicenter, retrospective, observational cohort study. We constructed an exponential growth model for both SCC and melanoma to estimate tumor growth between patient-reported onset and surgical excision at different time points., Results: Data from 200 patients with SCC of the head and neck and 1000 patients with cutaneous melanoma were included. An exponential growth curve was calculated for each tumor type and we estimated tumor size after 1, 2, and 3 months of potential surgical delay. The proportion of patients with T3 SCC (diameter >4cm or thickness >6 mm) increased from 41.5% (83 patients) in the initial study group to an estimated 58.5%, 70.5%, and 72% after 1, 2, and 3 months of delay. Disease-specific survival at 2, 5, and 10 years in patients whose surgery was delayed by 3 months decreased by 6.2%, 8.2%, and 5.2%, respectively. The proportion of patients with ultrathick melanoma (>6 mm) increased from 6.9% in the initial study group to 21.9%, 30.2%, and 30.2% at 1, 2, and 3 months. Five- and 10-year disease-specific survival both decreased by 14.4% in patients treated after a potential delay of 3 months., Conclusions: In the absence of adequate diagnosis and treatment of SCC and melanoma in the current lockdown situation in Spain, we can expect to see to a considerable increase in large and thick SCCs and melanomas. Efforts must be taken to encourage self-examination and facilitate access to dermatologists in order to prevent further delays., (© 2020 Published by Elsevier España, S.L.U. on behalf of AEDV.)
- Published
- 2020
- Full Text
- View/download PDF
24. IgA vasculitis as a presentation of human immunodeficiency virus infection.
- Author
-
Brandy-García AM, Santos-Juanes J, Suarez S, and Caminal-Montero L
- Subjects
- Adult, Female, HIV Infections diagnosis, Humans, Immunoglobulin A, Vasculitis immunology, HIV Infections complications, Vasculitis etiology
- Abstract
IgA vasculitis is a small-vessel vasculitis mediated by immune complexes. In clinical terms, it is characterized by palpable purpura in the lower limbs, joint involvement in the form of arthralgia or arthritis, and gastrointestinal and renal involvement (this will mark a poorer prognosis in adults). Infectious processes, mainly in the upper respiratory tract, are frequently found to be triggers. On the other hand, human immunodeficiency virus (HIV) causes immune dysfunction, which triggers hypergammaglobulinemia and can trigger autoimmune disorders. At times, this can affect the vascular endothelium, giving rise to vasculitic manifestations, although there are few reports in the literature of its role in the presentation of HIV., (Copyright © 2018 Sociedad Española de Reumatología y Colegio Mexicano de Reumatología. Publicado por Elsevier España, S.L.U. All rights reserved.)
- Published
- 2020
- Full Text
- View/download PDF
25. Miki (Mitotic Kinetics Regulator) Immunoexpression in Normal Liver, Cirrhotic Areas and Hepatocellular Carcinomas: a Preliminary Study with Clinical Relevance.
- Author
-
Fernández-Vega I, Santos-Juanes J, Camacho-Urkaray E, Lorente-Gea L, García B, Gutiérrez-Corres FB, Quirós LM, Guerra-Merino I, and Aguirre JJ
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Hepatocellular pathology, Cell Nucleus metabolism, Cytoplasm metabolism, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Ki-67 Antigen metabolism, Liver metabolism, Liver Cirrhosis metabolism, Liver Cirrhosis pathology, Liver Neoplasms mortality, Liver Neoplasms pathology, Male, Middle Aged, Carcinoma, Hepatocellular metabolism, Cell Cycle Proteins metabolism, Liver Neoplasms metabolism
- Abstract
Hepatocellular carcinoma (HCC) is the most common type of primary malignant tumor in the liver. One of the main features of cancer survival is the generalized loss of growth control exhibited by cancer cells, and Miki is a protein related to the immunoglobulin superfamily that plays an important role in mitosis. We aim to study protein expression levels of Miki in non-tumoral liver and 20 HCCs recruited from a Pathology Department. Clinical information was also obtained. A tissue microarray was performed, and immunohistochemical techniques applied to study protein expression levels of Miki. In normal liver, Miki was weakly expressed, showing nuclear staining in the hepatocytes. Cirrhotic areas and HCCs showed a variety of staining patterns. Most HCC samples showed positive expression, with three different staining patterns being discernible: nuclear, cytoplasmic and mixed. Statistical analysis showed a significant association between grade of differentiation, Ki-67 proliferative index, survival rates and staining patterns. This study has revealed the positive expression of Miki in normal liver, cirrhotic areas and HCCs. Three different staining patterns of Miki expression with clinical relevance were noted in HCCs.
- Published
- 2020
- Full Text
- View/download PDF
26. Comment on "Secukinumab drug survival in patients with psoriasis: A multicenter, real-world, retrospective study".
- Author
-
Palacios-García L, Gómez-de Castro C, Mir-Bonafé M, Calzón C, Galache C, and Santos-Juanes J
- Subjects
- Antibodies, Monoclonal, Antibodies, Monoclonal, Humanized, Humans, Retrospective Studies, Psoriasis
- Published
- 2019
- Full Text
- View/download PDF
27. Comment on 'Baseline patients' characteristics as predictors for therapeutic survival and response in patients with psoriasis on biological treatments'.
- Author
-
Gómez-de Castro C, Mir-Bonafé M, Arias-Martínez A, Martínez-Camblor P, Díaz-Coto S, and Santos-Juanes J
- Subjects
- Adalimumab, Humans, Psoriasis
- Published
- 2019
- Full Text
- View/download PDF
28. Lectin-like transcript 1 (LLT1) expression is associated with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
- Author
-
Santos-Juanes J, Fernández-Vega I, Lorenzo-Herrero S, Sordo-Bahamonde C, Martínez-Camblor P, García-Pedrero JM, Vivanco B, Galache-Osuna C, Vazquez-Lopez F, Gonzalez S, and Rodrigo JP
- Subjects
- Aged, Aged, 80 and over, Disease-Free Survival, Feasibility Studies, Female, Humans, Incidence, Kaplan-Meier Estimate, Male, Neoplasm Recurrence, Local diagnosis, Neoplasm Recurrence, Local epidemiology, Prognosis, Risk Assessment methods, Risk Factors, Skin pathology, Skin Neoplasms mortality, Squamous Cell Carcinoma of Head and Neck mortality, Biomarkers, Tumor metabolism, Lectins, C-Type metabolism, Lymphatic Metastasis pathology, Receptors, Cell Surface metabolism, Skin Neoplasms pathology, Squamous Cell Carcinoma of Head and Neck pathology
- Abstract
The interaction of lectin-like transcript 1 (LLT1) with CD161 inhibits Natural Killer cell activation. Overexpression of LLT1 contributes to the immunosuppressive properties of tumor cells. However, there are little data about LLT1 expression in human solid tumors. The objective of this paper is to investigate the relationship between LLT1 expression with the clinicopathologic features and its impact on the prognosis of head and neck cutaneous squamous cell carcinoma (cSCC). LLT1 expression was analyzed on paraffin-embedded tissue samples obtained from 100 patients with cSCC by immunohistochemistry. The estimator of Fine and Gray was used to estimate the cumulative incidence curves for relapse. Proportional Hazard models and Hazard ratios (HRs) were used for studying the risk of tumor relapse and mortality. LLT1 strong expression was a significant risk factor for nodal metastasis with crude and adjusted ratios (HRs) of 3.40 (95% CI 1.39-9.28) and 3.25 (95% CI 1.15-9.16); and for cSCC specific death of 6.17 (95% CI 1.79-21.2) and 6.10 (95% CI 1.45-25.7). Strong LLT1 expression is an independent predictor of nodal metastasis and poor disease-specific survival and it might be helpful for risk stratification of patients with cSCC.
- Published
- 2019
- Full Text
- View/download PDF
29. Plaque Psoriasis Flare and Peripheral Edema in a Patient Treated With Atezolizumab.
- Author
-
Santos-Juanes J, Munguía Calzada P, and Álvarez Fernández C
- Subjects
- Aged, Disease Progression, Humans, Male, Antibodies, Monoclonal, Humanized adverse effects, Antineoplastic Agents adverse effects, Drug Eruptions etiology, Edema chemically induced, Psoriasis chemically induced
- Published
- 2019
- Full Text
- View/download PDF
30. Correlation of focal adhesion kinase expression with nodal metastasis in patients with head and neck cutaneous squamous cell carcinoma.
- Author
-
Munguía-Calzada P, Fernández-Vega I, Martínez-Camblor P, Díaz-Coto S, García-Pedrero JM, Vivanco B, Osuna CG, Vazquez-Lopez F, Rodrigo JP, and Santos-Juanes J
- Subjects
- Adult, Aged, Biopsy, Needle, Cohort Studies, Disease-Free Survival, Female, Humans, Immunohistochemistry, Lymphatic Metastasis pathology, Male, Middle Aged, Predictive Value of Tests, Prognosis, Retrospective Studies, Skin Neoplasms epidemiology, Skin Neoplasms pathology, Squamous Cell Carcinoma of Head and Neck epidemiology, Squamous Cell Carcinoma of Head and Neck pathology, Survival Analysis, Biomarkers, Tumor genetics, Focal Adhesion Protein-Tyrosine Kinases metabolism, Lymph Nodes pathology, Skin Neoplasms metabolism, Squamous Cell Carcinoma of Head and Neck metabolism
- Abstract
Background: Focal adhesion kinase (FAK) and cortactin overexpression is frequently detected in a variety of cancers, and has been associated with poor clinical outcome. However, there are no data in cutaneous squamous cell carcinoma (cSCC)., Objective: To investigate the relationship of FAK and cortactin expression with the clinicopathologic features and the impact on the prognosis of cSCC patients., Methods: FAK and cortactin expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 100 patients with cSCC, and correlated with the clinical data., Results: FAK overexpression was a significant risk factor for nodal metastasis with crude and adjusted ratios (HRs) of 2.04, (95% CI [1.08-3.86], [P = 0.029]) and 2.23 (95% CI [1.01-4.91], [P = 0.047]), respectively. Cortactin expression was not a significant risk factor for nodal metastasis., Conclusion: These findings demonstrate that FAK overexpression is an independent predictor of nodal metastasis that might be helpful for risk stratification and management of patients with cSCC., (© 2018 Wiley Periodicals, Inc.)
- Published
- 2019
- Full Text
- View/download PDF
31. Cutaneous cryptococcosis.
- Author
-
Requena López S, Asensi Álvarez V, and Santos Juanes J
- Subjects
- Aged, Facial Dermatoses microbiology, HIV Infections diagnosis, Humans, Male, Pneumocystis carinii isolation & purification, Pneumonia, Pneumocystis diagnosis, Cryptococcosis pathology, Cryptococcus neoformans isolation & purification, Facial Dermatoses pathology, HIV Infections complications
- Published
- 2019
- Full Text
- View/download PDF
32. Sporadic Creutzfeldt-Jakob disease with glial PrP Res nuclear and perinuclear immunoreactivity.
- Author
-
Fernández-Vega I, Díaz-Lucena D, Azkune Calle I, Geijo M, Juste RA, Llorens F, Vicente Etxenausia I, Santos-Juanes J, Zarranz Imirizaldu JJ, and Ferrer I
- Subjects
- Aged, Creutzfeldt-Jakob Syndrome metabolism, Frontal Lobe metabolism, Frontal Lobe pathology, Humans, Immunohistochemistry, Male, Neuroglia metabolism, Creutzfeldt-Jakob Syndrome pathology, Inclusion Bodies pathology, Neuroglia pathology, Prion Proteins metabolism
- Abstract
Proteinase K-resistant prion protein (PrP
Res ) nuclear and perinuclear immunoreactivity in oligodendrocytes of the frontal cortex is found in one case of otherwise typical sporadic Creutzfeldt-Jakob disease (sCJD) type VV2a. The PrP nature of the inclusions is validated with several anti-PrP antibodies directed to amino acids 130-160 (12F10), 109-112 (3F4), 97-102 (8G8) and the octarepeat region (amino acids 59-89: SAF32). Cellular identification and subcellular localization were evaluated with double- and triple-labeling immunofluorescence and confocal microscopy using antibodies against PrP, glial markers, and histone H3. Based on review of the literature and our own experience, this is a very odd situation that deserves further validation in other cases., (© 2018 Japanese Society of Neuropathology.)- Published
- 2018
- Full Text
- View/download PDF
33. Comment on "Drug survival of apremilast for psoriasis in a real-world setting".
- Author
-
Santos-Juanes J, Velasco L, Munguía-Calzada P, Lozano A, and Gómez-Díez S
- Subjects
- Humans, Psoriasis, Thalidomide analogs & derivatives
- Published
- 2018
- Full Text
- View/download PDF
34. Reply to: "Prognostic significance of tumor budding in cutaneous squamous cell carcinoma".
- Author
-
Santos-Juanes J, Rodrigo JP, Gonzalez-Guerrero M, and Martínez-Camblor P
- Subjects
- Humans, Prognosis, Carcinoma, Squamous Cell, Skin Neoplasms
- Published
- 2018
- Full Text
- View/download PDF
35. Cutaneous and Mucosal Manifestations Associated with Celiac Disease.
- Author
-
Rodrigo L, Beteta-Gorriti V, Alvarez N, Gómez de Castro C, de Dios A, Palacios L, and Santos-Juanes J
- Subjects
- Alopecia Areata complications, Alopecia Areata diagnosis, Celiac Disease complications, Dermatitis Herpetiformis complications, Dermatitis Herpetiformis diagnosis, Dermatitis, Atopic complications, Dermatitis, Atopic diagnosis, Diet, Gluten-Free, Gastrointestinal Diseases complications, Gastrointestinal Diseases diagnosis, Glutens administration & dosage, Humans, Psoriasis complications, Psoriasis diagnosis, Rosacea complications, Rosacea diagnosis, Skin Diseases complications, Stomatitis, Aphthous complications, Stomatitis, Aphthous diagnosis, Urticaria complications, Urticaria diagnosis, Vasculitis, Leukocytoclastic, Cutaneous complications, Vasculitis, Leukocytoclastic, Cutaneous diagnosis, Celiac Disease diagnosis, Mucous Membrane pathology, Skin pathology, Skin Diseases diagnosis
- Abstract
Celiac disease (CD) is an immune-mediated, gluten-induced enteropathy that affects predisposed individuals of all ages. Many patients with CD do not report gastrointestinal symptoms making it difficult to reach an early diagnosis. On the other hand, CD is related to a wide spectrum of extra-intestinal manifestations, with dermatitis herpetiformis (DH) being the best characterized. These associated conditions may be the clue to reaching the diagnosis of CD. Over the last few years, there have been multiple reports of the association between CD and several cutaneous manifestations that may improve with a gluten-free diet (GFD). The presence of some of these skin diseases, even in the absence of gastrointestinal symptoms, should give rise to an appropriate screening method for CD. The aim of this paper is to describe the different cutaneous manifestations that have been associated with CD and the possible mechanisms involved.
- Published
- 2018
- Full Text
- View/download PDF
36. Brains with sporadic Creutzfeldt-Jakob disease and copathology showed a prolonged end-stage of disease.
- Author
-
Miguelez-Rodriguez A, Santos-Juanes J, Vicente-Etxenausia I, Perez de Heredia-Goñi K, Garcia B, Quiros LM, Lorente-Gea L, Guerra-Merino I, Aguirre JJ, and Fernandez-Vega I
- Subjects
- Aged, Amyloid beta-Peptides analysis, Autopsy, Biological Specimen Banks, Biopsy, Creutzfeldt-Jakob Syndrome mortality, DNA-Binding Proteins analysis, Dementia mortality, Disease Progression, Female, Humans, Immunohistochemistry, Kaplan-Meier Estimate, Male, Middle Aged, Phosphorylation, Retrospective Studies, Spain, alpha-Synuclein analysis, tau Proteins analysis, Brain metabolism, Brain pathology, Creutzfeldt-Jakob Syndrome metabolism, Creutzfeldt-Jakob Syndrome pathology, Dementia metabolism, Dementia pathology, Nerve Tissue Proteins analysis
- Abstract
Aims: To investigate the expression of major proteins related to primary neurodegenerative diseases and their prognostic significance in brains with Creutzfeldt-Jakob disease (CJD)., Materials and Methods: Thirty consecutive cases of confirmed CJD during the period 2010-2015 at Basque Brain bank were retrospectively reviewed. Moreover, major neurodegenerative-associated proteins (phosphorylated Tau, 4R tau, 3R tau, alpha-synuclein, TDP43, amyloid beta) were tested. Clinical data were reviewed. Cases were divided according to the presence or absence of copathology. Survival curves were also determined., Results: Copathology was significantly associated with survival in brains with CJD (4.2±1.2 vs 9.2±1.9; P=0.019) and in brains with MM1/MV1 CJD (2.1±1.0 vs 6.7±2.8; P=0.012). Besides, the presence of more than one major neurodegenerative-associated protein was significantly associated with survival (4.2±1.2 vs 10.7±2.6; P=0.017). Thus, univariate analyses further pointed out variables significantly associated with better survival: copathology in CJD (HR=0.430; P=0.033); more than one neurodegenerative-associated protein in CJD (HR=0.369; P=0.036) and copathology in MM1/MV1 CJD (HR=0.525; P=0.032)., Conclusion: The existence of copathology significantly prolongs survival in patients with rapidly progressive dementia due to CJD. The study of major neurodegenerative-associated proteins in brains with CJD could allow us to further understand the molecular mechanisms behind prion diseases., Competing Interests: Competing interests: None declared., (© Article author(s) (or their employer(s) unless otherwise stated in the text of the article) 2018. All rights reserved. No commercial use is permitted unless otherwise expressly granted.)
- Published
- 2018
- Full Text
- View/download PDF
37. Establishing cut-off points with clinical relevance for bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1 expression in glioblastoma - a short report.
- Author
-
Camacho-Urkaray E, Santos-Juanes J, Gutiérrez-Corres FB, García B, Quirós LM, Guerra-Merino I, Aguirre JJ, and Fernández-Vega I
- Subjects
- Female, Humans, Immunohistochemistry, Male, Middle Aged, SOXC Transcription Factors metabolism, Tissue Array Analysis, WT1 Proteins metabolism, Cyclin D1 metabolism, Cyclin-Dependent Kinase Inhibitor p16 metabolism, Cyclin-Dependent Kinase Inhibitor p21 metabolism, Glioblastoma metabolism, Tumor Suppressor Protein p53 metabolism
- Abstract
Purpose: Glioblastoma (GBM) ranks among the most challenging cancers to treat and there is an urgent need for clinically relevant prognostic and diagnostic biomarkers. Here, we set out to investigate the expression of eight proteins (bcl-2, cyclin D1, p16, p21, p27, p53, Sox11 and WT1) in GBM with the specific aim to establish immunohistochemistry cut-off points with clinical relevance., Methods: Immunohistochemistry (IHC) was used to examine protein expression in 55 surgical GBM specimens using H-scores, and IHC cut-off points were established using the Cutoff Finder web platform. Protein co-expression and its correlation with histopathological features were assessed, and cases were classified according to IDH1 mutation status. Survival curves were determined using Kaplan-Meier analyses., Results: Clinical and molecular parameters found to be correlated with overall survival (OS) were tumor size (r = -0.278; p = 0.048), p53 (r = -0.452; p = 0.001), p16 (r = 0.351; p = 0.012) and Sox11 (r = 0.324; p = 0.020). In addition, we found that tumor size correlated with cyclin D1 (r = -0.282; p = 0.037), p53 (r = 0.269; p = 0.041), Sox11 (r = -0.309; p = 0.022) and WT1 (r = -0.372; p = 0.003). Variables found to be significantly associated with IDH1 mutation status were OS (p < 0.01), age (p < 0.01), cyclin D1 (p = 0.046), p16 (p = 0.019) and Sox11 (p = 0.012). Variables found to be significantly associated with a poor survival were tumor size >5 cm (p < 0.001), bcl-2 score > 40 (p = 0.034), cyclin D1 score ≤ 70 (p = 0.004), p16 score ≤ 130 (p = 0.005), p53 score > 20 (p = 0.003), Sox11 score ≤ 40 (p < 0.001) and WT1 score ≤ 270 (p = 0.02)., Conclusions: Correlations between protein biomarkers and main clinical GBM variables were identified. The establishment of distinct biomarker cut-off points may enable clinicians and pathologists to better weigh their prognostic value.
- Published
- 2018
- Full Text
- View/download PDF
38. Cutaneous Solitary Fibrous Tumor: A Spindle Cell Neoplasm With Distinctive Immunohistochemical Features.
- Author
-
Santos-Juanes J, García-García B, Hidalgo Y, and Vivanco B
- Subjects
- Adult, Carcinoma pathology, Female, Humans, Immunohistochemistry, Skin Neoplasms pathology, Solitary Fibrous Tumors pathology
- Published
- 2018
- Full Text
- View/download PDF
39. Melanoma, eruptive naevi and natalizumab: Causal relation or coincidence?
- Author
-
Munguía-Calzada P, Vivanco B, Oliva-Nacarino P, and Santos-Juanes J
- Subjects
- Female, Humans, Melanoma pathology, Middle Aged, Multiple Sclerosis drug therapy, Skin Neoplasms pathology, Immunologic Factors adverse effects, Melanoma chemically induced, Natalizumab adverse effects, Nevus, Pigmented chemically induced, Skin Neoplasms chemically induced
- Published
- 2017
- Full Text
- View/download PDF
40. Author's response to a reply to 'Sentinel lymph node biopsy plus wide local excision vs. wide local excision alone for primary cutaneous melanoma: a systematic revive and meta-analysis'.
- Author
-
Santos-Juanes J and Martínez-Camblor P
- Subjects
- Humans, Lymph Node Excision, Lymphatic Metastasis, Sentinel Lymph Node Biopsy, Melanoma surgery, Skin Neoplasms surgery
- Published
- 2017
- Full Text
- View/download PDF
41. Tumor programmed cell death ligand 1 expression correlates with nodal metastasis in patients with cutaneous squamous cell carcinoma of the head and neck.
- Author
-
García-Pedrero JM, Martínez-Camblor P, Diaz-Coto S, Munguia-Calzada P, Vallina-Alvarez A, Vazquez-Lopez F, Rodrigo JP, and Santos-Juanes J
- Subjects
- Aged, Aged, 80 and over, Female, Humans, Lymphatic Metastasis, Male, Retrospective Studies, B7-H1 Antigen biosynthesis, Carcinoma, Squamous Cell metabolism, Carcinoma, Squamous Cell secondary, Head and Neck Neoplasms metabolism, Head and Neck Neoplasms pathology, Skin Neoplasms metabolism, Skin Neoplasms pathology
- Abstract
Background: Binding of tumor-expressed programmed cell death ligand 1 (PD-L1) to the programmed cell death 1 (PD-1) surface receptor blocks T-cell activation thereby leading to immune evasion. Tumor PD-L1 expression has been associated with poor outcome in a wide variety of cancers; however, data in cutaneous squamous cell carcinoma (cSCC) are scarce and conflicting., Objective: To investigate the relationship of tumor PD-L1 expression with the clinicopathologic features and prognosis of cSCC., Methods: PD-L1 expression was analyzed by immunohistochemistry on paraffin-embedded tissue samples from 100 patients with cSCC. Cumulative/dynamic receiver operating characteristic curve was used to determine the optimal PD-L1 threshold. Kaplan-Meier estimators and Cox proportional hazards regression models were also used., Results: On the basis of cumulative/dynamic receiver operating characteristic curves, we defined the cut-off score for PD-L1 expression as ≥25% of tumor cells positively stained. PD-L1 expression was a significant risk factor for nodal metastasis with crude and adjusted hazard ratios of 3.39 (1.71-6.65) and 6.54 (2.28-18.78), respectively., Limitations: This is a retrospective study limited to cSCC of the head and neck., Conclusion: These findings indicate that tumor PD-L1 expression predicts increased risk for nodal metastasis in patients with cSCC., (Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
42. Painful subcutaneous nodule.
- Author
-
Santos-Juanes J, Galache C, and Blanco V
- Subjects
- Calcinosis pathology, Female, Humans, Middle Aged, Radiography, Tenosynovitis pathology, Toes, Calcinosis diagnostic imaging, Tenosynovitis diagnostic imaging
- Published
- 2017
- Full Text
- View/download PDF
43. The adverse prognostic effect of tumor budding on the evolution of cutaneous head and neck squamous cell carcinoma.
- Author
-
Gonzalez-Guerrero M, Martínez-Camblor P, Vivanco B, Fernández-Vega I, Munguía-Calzada P, Gonzalez-Gutierrez MP, Rodrigo JP, Galache C, and Santos-Juanes J
- Subjects
- Aged, Aged, 80 and over, Carcinoma, Squamous Cell mortality, Female, Head and Neck Neoplasms mortality, Humans, Lymphatic Metastasis, Male, Middle Aged, Neoplasm Invasiveness, Prognosis, Retrospective Studies, Squamous Cell Carcinoma of Head and Neck, Survival Rate, Carcinoma, Squamous Cell pathology, Head and Neck Neoplasms pathology
- Abstract
Background: Tumor budding is a readily detectable histopathologic feature that has been recognized as an adverse prognostic factor in several human cancers., Objective: We sought to assess the correlation of tumor budding with the clinicopathologic features and the prognostic value of tumor budding in cutaneous squamous cell carcinoma (cSCC)., Methods: Forty-nine primary nonmetastatic and 49 primary metastatic cSCCs to regional lymph nodes were retrospectively studied. Statistical analyses were carried out to assess the relationship between tumor budding, clinicopathologic parameters, and patient survival., Results: Tumor budding was observed in 45 cases of 98 (46%). High-intensity budding (≥5 tumor buds) was observed in 20 tumors. Presence of tumor buds was a significant risk factor for nodal metastasis with crude and adjusted hazard ratios (HRs) of 8.92 (95% CI, 4.39-18.1) and 6.93 (95% CI, 3.30-14.5), respectively, and for reduced overall survival time (crude and adjusted HRs of 2.03 [95% CI, 1.26-3.28] and 1.72 [95% CI, 1.05-2.83], respectively)., Limitations: This was a retrospective study limited to cSCCs of the head and neck. Examined tumors were >2 mm thick, and all were from a primary excision., Conclusion: These results indicate an increased frequency of nodal metastasis and risk of death in patients with tumor buds., (Copyright © 2017 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.)
- Published
- 2017
- Full Text
- View/download PDF
44. Comment on «Distant Cutaneous Metastases of Prostate Cancer: A Report of 2 Cases».
- Author
-
Santos-Juanes J, Fernández-Vega I, and Vivanco B
- Subjects
- Humans, Male, Skin, Prostatic Neoplasms, Skin Neoplasms
- Published
- 2017
- Full Text
- View/download PDF
45. Sentinel lymph node biopsy plus wide local excision vs. wide location excision alone for primary cutaneous melanoma: a systematic review and meta-analysis.
- Author
-
Santos-Juanes J, Fernández-Vega I, Galache Osuna C, Coto-Segura P, and Martínez-Camblor P
- Subjects
- Humans, Prognosis, Melanoma pathology, Melanoma surgery, Sentinel Lymph Node Biopsy methods, Skin Neoplasms pathology, Skin Neoplasms surgery
- Abstract
Background: Sentinel lymph node biopsy and wide local excision of the primary melanoma (SLNB) is now a standard staging procedure for patients with melanomas 1 mm or more in thickness, but its therapeutic benefit is not clear., Objective: To determine whether there is an association between performance of SLNB and patient prognosis., Methods: Studies assessing the association between performance of SLNB and patient prognosis were pooled from MEDLINE, EMBASE, PubMed, Cochrane Database of Systematic Reviews and Google Scholar. From each study, first author's last name, publication year, origin country, type of study design, characteristics of participants and the Hazard risk (HR) for melanoma specific survival (MSS) with the corresponding 95% confidence interval (95% CI) were collected. Methodological assessment of the studies was evaluated using the Newcastle-Ottawa scale (NOS) and the 'Risk of bias' tool detailed in the Cochrane Handbook for Systematic Reviews of Interventions. Meta-analyses for the global HR were performed. In addition, in order to explore the sources of heterogeneity among the studies, sensitivity analyses are also provided., Results: A total of six studies with 8764 patients who had undergone SLNB and 11054 patients who had undergone wide location excision alone (WLEA) were identified for the analysis. The indicators suggest that the heterogeneity is low: τ
2 = 0; H = 1 [1; 1.74]; I2 = 0% [0%; 66.5%]. Evidence for publication bias was not found (Egger's test P = 0.4654). The pooled MSS HR from fixed effects analysis was determined to be 0.88 (95% CI = 0.80-0.96)., Conclusions: Although no significant survival difference was observed in four of the six series, the pooling summary data from all the studies that deal with this issue suggested that SLNB is associated with a significantly better outcome compared with WLEA for localized melanoma., (© 2016 European Academy of Dermatology and Venereology.)- Published
- 2017
- Full Text
- View/download PDF
46. Upregulated Expression of Heparanase and Heparanase 2 in the Brains of Alzheimer's Disease.
- Author
-
García B, Martín C, García-Suárez O, Muñiz-Alonso B, Ordiales H, Fernández-Menéndez S, Santos-Juanes J, Lorente-Gea L, Castañón S, Vicente-Etxenausia I, Piña Batista KM, Ruiz-Díaz I, Caballero-Martínez MC, Merayo-Lloves J, Guerra-Merino I, Quirós LM, and Fernández-Vega I
- Subjects
- Aged, Aged, 80 and over, Female, Glucuronidase genetics, Humans, Male, Middle Aged, RNA, Messenger metabolism, Alzheimer Disease pathology, Alzheimer Disease physiopathology, Brain enzymology, Glucuronidase metabolism, Up-Regulation physiology
- Abstract
Background: Heparan sulfate proteoglycans (HSPGs) promote amyloid-β peptide and tau fibrillization in Alzheimer's disease (AD) and provide resistance against proteolytic breakdown. Heparanase (HPSE) is the only enzyme that cleaves heparan sulfate (HS). Heparanase 2 (HPSE2) lacks HS-degrading activity, although it is able to interact with HS with high affinity., Objective: To analyze HPSE and HPSE2 expressions at different stages of AD., Methods: RT-PCR was used to analyze transcription levels of both heparanases at different stages of AD, and immunohistochemistry was performed to localize each one in different parts of the brain., Results: Both proteins appeared overexpressed at different stages of AD. Immunohistochemistry indicated that the presence of the heparanases was related to AD pathology, with intracellular deposits found in degenerated neurons. At the extracellular level, HPSE was observed only in neuritic plaques with a fragmented core, while HPSE2 appeared in those with compact cores as well., Conclusion: Given the involvement of HSPGs in AD pathology, there would seem to be a relationship between the regulation of heparanase expression, the features of the disease, and a possible therapeutic alternative.
- Published
- 2017
- Full Text
- View/download PDF
47. Primary amelanotic rhabdoid melanoma of the forehead.
- Author
-
Fernández-Vega I, Santos-Juanes J, and Fresno-Forcelledo MF
- Subjects
- Aged, 80 and over, Facial Neoplasms surgery, Fatal Outcome, Forehead surgery, Humans, Male, Margins of Excision, Melanoma, Amelanotic surgery, Rhabdoid Tumor surgery, Skin Neoplasms surgery, Surgical Flaps, Facial Neoplasms diagnosis, Melanoma, Amelanotic diagnosis, Rhabdoid Tumor diagnosis, Skin Neoplasms diagnosis
- Published
- 2016
- Full Text
- View/download PDF
48. Sporadic adult-onset leucodystrophy with axonal spheroids and pigmented glia with no mutations in the known targeted genes.
- Author
-
Fernández-Vega I, Pérez de Heredia-Goñi K, Santos-Juanes J, Goñi Imizcoz M, Zaldumbide L, Zarranz JJ, and Ferrer I
- Subjects
- Age of Onset, Axons pathology, Female, Genetic Testing, Humans, Leukodystrophy, Metachromatic genetics, Leukodystrophy, Metachromatic pathology, Middle Aged, Mutation, Adaptor Proteins, Signal Transducing genetics, Axons physiology, Leukodystrophy, Metachromatic diagnosis, Membrane Glycoproteins genetics, Membrane Proteins genetics, Neuroglia pathology, Receptors, Immunologic genetics
- Abstract
Aims: Adult-onset orthochromatic leucodystrophy, associated with pigmented macrophages and hereditary diffuse leucoencephalopathy with spheroids, are two disorders with similar clinical manifestations, radiological characteristics and neuropathological findings. Mutations in the colony-stimulating factor 1 receptor (CSF1R) gene are the hallmark of this spectrum of disease. Furthermore, polycystic membranous lipomembranous osteodysplasia with sclerosing leucoencephalopathy is caused by mutations in two genes, DAP12 and TREM2, which encode proteins involved in the same pathways as CSF1R. We describe a case of sporadic adult-onset orthochromatic leucodystrophy associated with pigmented macrophages diagnosed by biopsy without harbouring mutations in the known targeted genes., Methods and Results: A 51-year-old woman, with no familial history of neurological diseases, developed a progressive neurological deterioration showing inappropriate behaviour, ataxia, spasticity, axial dystonia and agitation. Radiological images and a stereotaxic biopsy were conclusive with adult-onset orthochromatic leucodystrophy associated with pigmented macrophages. Genetic analysis did not show mutations in either CSF1R, DAP12 or TREM2., Conclusions: We add support to the idea that all these entities are closely related diseases linked to a convergent metabolic pathway, but caused by different genes or perhaps by the combination of individually non-pathogenic variations of selected genes. Genetic defects are still barely known in a substantial number of adult leucodystrophies., (© 2015 John Wiley & Sons Ltd.)
- Published
- 2016
- Full Text
- View/download PDF
49. CDKAL1 gene variants affect the anti-TNF response among Psoriasis patients.
- Author
-
Coto-Segura P, Batalla A, González-Fernández D, Gómez J, Santos-Juanes J, Queiro R, Alonso B, Iglesias S, and Coto E
- Subjects
- Adult, Alleles, Female, Gene Frequency, Genotype, Humans, Male, Middle Aged, Polymorphism, Single Nucleotide genetics, Psoriasis pathology, Skin pathology, Treatment Outcome, tRNA Methyltransferases, Cyclin-Dependent Kinase 5 genetics, Psoriasis drug therapy, Psoriasis genetics, Tumor Necrosis Factor Inhibitors
- Abstract
The heterogeneous response to anti-TNF biological drugs among Psoriasis (Psor) patients might be explained by gene variants linked to the risk for Psor. Common variants in the CDKAL1 gene have been associated with the risk of developing Psor. Our hypothesis was that these variants could also influence the response to anti-TNFs among Psor-patients. A reduction of at least 75% in the Psoriasis area and severity index (PASI 75) at week 24 was considered a positive response to treatment. A total of 116 patients (78 responders and 38 non-responders) were genotyped for the CDKAL1 rs6908425, rs4712523, rs111739077, and rs77152992 (p.P409L) single nucleotide polymorphisms. Allele and genotype frequencies differed between the two response groups, with the highest difference for the rs6908425: CC homozygotes were significantly more common among responders (72% vs. 45%; p=0.005; OR=3.14, 95%CI=1.40-7.05). In conclusion, our data suggested that CDKAL1 gene variants have a significant effect on the response to anti-TNF therapies among Psor patients. If confirmed on other large cohorts of patients, the genotyping of these variants might help to predict the biological response., (Copyright © 2015 Elsevier B.V. All rights reserved.)
- Published
- 2015
- Full Text
- View/download PDF
50. Thyroid nodule as a first sign of progression in uterine cervical carcinoma.
- Author
-
Fuentes-Martínez N, Santos Juanes J, Vivanco-Allende B, and Gagatek SG
- Subjects
- Adult, Biomarkers, Tumor analysis, Biopsy, Fine-Needle, Carcinoma, Squamous Cell diagnostic imaging, Carcinoma, Squamous Cell virology, Fatal Outcome, Female, Human papillomavirus 16 isolation & purification, Humans, Palliative Care, Papillomavirus Infections diagnosis, Thyroid Neoplasms diagnostic imaging, Thyroid Neoplasms pathology, Thyroid Neoplasms virology, Thyroid Nodule diagnostic imaging, Thyroid Nodule pathology, Tomography, X-Ray Computed, Carcinoma, Squamous Cell secondary, Thyroid Neoplasms secondary, Thyroid Nodule etiology, Uterine Cervical Neoplasms pathology
- Published
- 2015
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.